Overview

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
TG Therapeutics, Inc.
Collaborator:
James P. Wilmot Cancer Center
Treatments:
Lenalidomide
Venetoclax